High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
- PMID: 18641099
- DOI: 10.1378/chest.07-2444
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
Abstract
Background: Lung disease has become the leading cause of mortality and morbidity in scleroderma (SSc) patients. The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized.
Methods: Baseline HRCT scan images of 162 participants randomized into a National Institutes of Health-funded clinical trial were compared to clinical features, pulmonary function test measures, and BAL fluid cellularity. The extent and distribution of interstitial lung disease HRCT findings, including pure ground-glass opacity (pGGO), pulmonary fibrosis (PF), and honeycomb cysts (HCs), were recorded in the upper, middle, and lower lung zones on baseline and follow-up CT scan studies.
Results: HRCT scan findings included 92.9% PF, 49.4% pGGO, and 37.2% HCs. There was a significantly higher incidence of HCs in the three zones in lcSSc patients compared to dcSSc patients (p = 0.034, p = 0.048, and p = 0.0007, respectively). The extent of PF seen on HRCT scans was significantly negatively correlated with FVC (r = - 0.22), diffusing capacity of the lung for carbon monoxide (r = - 0.44), and total lung capacity (r = - 0.36). A positive correlation was found between pGGO and the increased number of acute inflammatory cells found in BAL fluid (r = 0.28). In the placebo group, disease progression was assessed as 30% in the upper and middle lung zones, and 45% in the lower lung zones. No difference in the progression rate was seen between lcSSc and dcSSc patients.
Conclusions: PF and GGO were the most common HRCT scan findings in symptomatic SSc patients. HCs were seen in more than one third of cases, being more common in lcSSc vs dcSSc. There was no relationship between progression and baseline PF extent or lcSSc vs dcSSc.
Trial registration: Clinicaltrials.gov Identifier: NCT00004563.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- P50 HL067665/HL/NHLBI NIH HHS/United States
- R01 HL089758/HL/NHLBI NIH HHS/United States
- R01 HL072424/HL/NHLBI NIH HHS/United States
- U01 HL060587/HL/NHLBI NIH HHS/United States
- U01 HL 60839/HL/NHLBI NIH HHS/United States
- U01 HL 60550/HL/NHLBI NIH HHS/United States
- P01 HL067665/HL/NHLBI NIH HHS/United States
- U01 HL 60606/HL/NHLBI NIH HHS/United States
- R01 DA008254/DA/NIDA NIH HHS/United States
- R01 HL080343/HL/NHLBI NIH HHS/United States
- U01 HL 60682/HL/NHLBI NIH HHS/United States
- U01 HL 60587-01A1/HL/NHLBI NIH HHS/United States
- U01 HL 60794/HL/NHLBI NIH HHS/United States
- U01 HL 60597/HL/NHLBI NIH HHS/United States
- U01 HL 60823/HL/NHLBI NIH HHS/United States
- U01 HL 60587/HL/NHLBI NIH HHS/United States
- M01 RR000865/RR/NCRR NIH HHS/United States
- U01 HL 60895/HL/NHLBI NIH HHS/United States
- U01 HL60750/HL/NHLBI NIH HHS/United States
- R37 DA003018/DA/NIDA NIH HHS/United States
- U01 HL 60748/HL/NHLBI NIH HHS/United States
